(Q24235551)

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Food allergy to apple and specific immunotherapy with birch pollen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Allergic rhinitis and its impact on asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Towards evidence-based medicine in specific grass pollen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Recommendations for appropriate sublingual immunotherapy clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Sublingual immunotherapy: a comprehensive review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Sublingual immunotherapy for allergic respiratory diseases: an evaluation of meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Sublingual immunotherapy for allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

[Sublingual immunotherapy with cat epithelial extract. Personal experience]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Immunomodulation during sublingual therapy in allergic children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Anaphylaxis to sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Anaphylaxis by latex sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Anaphylaxis to multiple pollen allergen sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Clinical efficacy and safety of preseasonal sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitic patients. A double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021

Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002893.PUB2

7 January 2021